Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06046222 · ClinicalTrials.gov registry record · Phase 2
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
A Phase 2 study of Eosinophilic Granulomatosis With Polyangiitis and Churg-Strauss Syndrome, sponsored by NS Pharma.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 20
- Study locations
NCT06046222 is a Phase 2 study of Eosinophilic Granulomatosis With Polyangiitis and Churg-Strauss Syndrome that is actively recruiting participants, run by NS Pharma. The registered enrollment target is 45 participants, below the 621-participant average among 3 other Eosinophilic Granulomatosis With Polyangiitis trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT06046222, a Phase 2 study of Eosinophilic Granulomatosis With Polyangiitis and Churg-Strauss Syndrome, is actively recruiting participants, sponsored by NS Pharma.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will enroll male and female subjects who are 18 years of age or older with Eosinophilic Granulomatosis With Polyangiitis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NS-229
Study Locations (20)
Other
- CHU Nice - Nice
- Hopital Cochin - Paris
- Chu Rangueil - Toulouse
- Istituto Auxologico Italiano IRCCS - Milan
- Fondazione Policlinico Universitario Campus Bio-Medico - Roma
- Azienda Provinciale per i Servizi Sanitari Provincia Autonoma Trento - Trento
- Azienda Ospedaliera Universitaria Integrata Verona - Verona
Ohio
- Cleveland Clinic - Cleveland
- The Ohio State University Wexner Medical Center - Columbus
Ontario
- St Joseph's Healthcare Hamilton - Hamilton
- University of Toronto - Toronto
Colorado
- National Jewish Health - Denver
Minnesota
- Mayo Clinic - Rochester
Pennsylvania
- University of Pennsylvania - Philadelphia
South Carolina
- Medical University of South Carolina - Charleston
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2023-12-20 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06046222
The ClinicalTrials.gov registry entry for NCT06046222 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 621-participant average among 3 other Eosinophilic Granulomatosis With Polyangiitis trials with a reported enrollment target (93% lower). The listed sponsor is NS Pharma, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Eosinophilic Granulomatosis With Polyangiitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06046222 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Ohio, Ontario.
Frequently Asked Questions
What is clinical trial NCT06046222 about?
NCT06046222 is a clinical study titled "Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis". This study will enroll male and female subjects who are 18 years of age or older with Eosinophilic Granulomatosis With Polyangiitis.
What is the current status of trial NCT06046222?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2023-12-20. Estimated completion is 2026-07.
What conditions does trial NCT06046222 study?
This clinical trial studies the following conditions: Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome.
What interventions are being tested in trial NCT06046222?
The interventions under investigation include: Placebo (DRUG), NS-229 (DRUG).
Who is sponsoring clinical trial NCT06046222?
This trial is sponsored by NS Pharma, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06046222 being conducted?
This trial has 20 study locations across Colorado, Minnesota, Ohio, Pennsylvania, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Granulomatosis With Polyangiitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Eosinophilic Granulomatosis With Polyangiitis
All registered trials for this condition
Churg-Strauss Syndrome
All registered trials for this condition
Colorado
All trials with a study site in Colorado
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.